A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Conditions
Metastatic Solid Tumors · Advanced Non-squamous Non-small-cell Lung Cancer · Advanced Colorectal Cancer · Advanced Pancreatic Ductal Adenocarcinoma · Advanced Gastric Cancer · Advanced Gastroesophageal Junction Cancer · Advanced Esophageal Adenocarcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States
Sidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore, Maryland, United States
The University of Texas Md Anderson Cancer Center, Houston, Texas, United States
Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia
Monash Health, Clayton, Victoria, Australia
Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
Linear Clinical Research, Nedlands, Western Australia, Australia
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China
Beijing Cancer Hospital, Beijing, Beijing Municipality, China
Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi, China
Auckland City Hospital, Auckland, New Zealand
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea
Samsung Medical Center, GangnamGu, Seoul Teugbyeolsi, South Korea
Severance Hospital Yonsei University Health System, SeodaemunGu, Seoul Teugbyeolsi, South Korea
Seoul National University Hospital, Seoul, Seoul Teugbyeolsi, South Korea
Asan Medical Center, SongpaGu, Seoul Teugbyeolsi, South Korea
Study leads
Study Director
BeiGene